Tivicay approved in Europe in new dispersible tablet for children with HIVViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living Share XTivicay approved in Europe in new dispersible tablet for children with HIVhttps://pharmaphorum.com/news/tivicay-approved-in-europe-in-new-dispersible-tablet-for-children-with-hiv/
GSK ends 2020 with multi-million dollar deal frenzy to boost R&DGlaxoSmithKline has closed the year with a flurry of deals, leaving its development pipeline bulging like Santa’s sack Share XGSK ends 2020 with multi-million dollar deal frenzy to boost R&Dhttps://pharmaphorum.com/news/gsk-closes-2020-with-four-deals/
GSK’s Benlysta claims first FDA okay for lupus kidney damageGlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up Share XGSK’s Benlysta claims first FDA okay for lupus kidney damagehttps://pharmaphorum.com/news/gsks-benlysta-claims-first-fda-okay-for-lupus-kidney-damage/
Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypsSanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps Share XSanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypshttps://pharmaphorum.com/news/dupixent-on-notice-as-fda-reviews-gsks-nucala-for-nasal-polyps/
VC firm SR One completes GSK spin-out, raising $500mTrans-Atlantic biotech venture capital firm SR One has completed its spin-out from GlaxoSmithKline and closed its first fund Share XVC firm SR One completes GSK spin-out, raising $500mhttps://pharmaphorum.com/news/vc-sr-one-completes-gsk-spin-out-raising-500m/
Vaccine sales recover at GSK in Q3, but lockdown fears weigh on sharesGlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the Share XVaccine sales recover at GSK in Q3, but lockdown fears weigh on shareshttps://pharmaphorum.com/news/vaccine-sales-recover-at-gsk-in-q3-but-lockdown-fears-weigh-on-shares/
Lilly asks FDA for emergency clearance for COVID-19 antibody therapyEli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing Share XLilly asks FDA for emergency clearance for COVID-19 antibody therapyhttps://pharmaphorum.com/news/lilly-asks-fda-for-emergency-clearance-for-covid-19-antibody-therapy/
GSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rivalGlaxoSmithKline and partner Vir Biotechnology are to expand a trial of an experimental antibody to treat COVID-19, putting Share XGSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rivalhttps://pharmaphorum.com/news/gsk-and-vir-expand-covid-19-antibody-trial-after-trumps-treatment-with-regenerons-rival/
AZ halts COVID-19 vaccine after safety scare, as UK faces ‘second wave’It’s a bleak day in the fight against COVID-19, after the UK banned social gatherings of more than Share XAZ halts COVID-19 vaccine after safety scare, as UK faces ‘second wave’https://pharmaphorum.com/news/az-halts-covid-19-vaccine-after-safety-scare-as-uk-faces-second-wave/
